Catalent to acquire Juniper Pharmaceuticals for $11.50/share
Note: This section contains information in English only.
Tue, 03 Jul 2018 10:31:27 GMT
Source: Dukascopy Bank SA
On Tuesday, the US drug contract producer stated it would acquire Juniper Pharmaceuticals for $11.50 a share in cash, valuing the company at around $127.7M.
For further information regarding potential cooperation, please call us or make callback request.
To learn more about Dukascopy Bank Binary Options
/ Forex trading platform, SWFX and other trading related information, please call us or make callback request.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information, please call us or make callback request.
To learn more about Business Introducer and other trading related information, please call us or make callback request.
For further information regarding potential cooperation, please call us or make callback request.